DNER and prostate cancer: On a broader level, our RNA-sequencing data using human prostate cancer cell lines showed that BET bromodomain inhibition alters the expression of a number of immune-related genes, and that JQ1 treatment further upregulates antigen presentation pathways initiated by IFN-γ treatment, while potentially decreasing signaling through certain growth factor pathways (Fig. 4).